Adlai Nortye vs Inventiva
ANL and IVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANL and IVA compare
Inventiva scores higher on the StockData Score (1 against 0 for Adlai Nortye), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANL | IVA |
|---|---|---|
| Size and price | ||
| Share price | $10.61 | $3.68 |
| Change, 1 year | 559% | −9.1% |
| Change, 5 years | – | −72.1% |
| Beta (5Y) | 1.67 | 0.83 |
| Employees | – | 77 |
| StockData Score | ||
| Total score | 0 | 1 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | – | −51.3% |
| Revenue growth, 5Y average | – | 64.5% |
| Profitability | ||
| Operating margin | −714% (better) | −3146% |
| Net margin | −711% | – |
| FCF margin | −673% | – |
| Financial health | ||
| Interest coverage | −23.3× | −0.7× (better) |
| Current ratio | 0.65 | 3.81 (better) |
| Piotroski F-score | 1 | – |
| Ownership | ||
| Held by institutions | 22.1% | 45.2% |
| Held by insiders | 14.7% | 24.7% |
| Insider net buying, 12 months | −$411K | – |
Go deeper
- ANL stock overview
- ANL income statement
- ANL valuation and score
- IVA stock overview
- IVA income statement
- IVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.